Events

På denne side finder du de seneste nyheder og events, hvor Medac deltager.

  1. EBMT 2019

    24 mars, 2019 - 27 mars, 2019

  2. Nordic Congress of Dermatology & Venereology 2019

    8 maj, 2019 - 10 maj, 2019

  3. NUF Congress 2019

    5 juni, 2019 - 8 juni, 2019

  4. EULAR 2019 (European league against rheumatism)

    12 juni, 2019 - 15 juni, 2019

Nyheder

Lomustine forbedrer overlevelsen for glioblastompatienter med metyleret MGMT promotor

Et studie anført af Prof. Herrlingen i Bonn, som blev præsenteret på 2017-mødet for Society for NeuroOncology, er nu publiceret i ”The Lancet”. „Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3” (Lancet 2019;393:678-88) Dette studie kan anses som en milepæl, […]

Press release – New conditioning therapy by medac about to receive European approval

Positive opinion from the CHMP for TRECONDI®  (treosulfan) by medac for toxicity-reducing conditioning for allogeneic haematopoietic stem cell transplantation. Further information can be found by clicking here

Medac has received the Yellow Hand Award

Medac received the Yellow Hand Award for the second consecutive time during the European Conference Oncology Pharmacy. The Yellow Hand Award is given by ESOP, European Society of Oncology Pharmacy. The Yellow Hand Award is awarded to companies who ensure safe transportation and handling of cystostatics throughout the complete supply chain and was first given in […]

Press release – First marketing authorisation worldwide for methotrexate in moderate psoriasis

Medac’s marketing authorisation extension gives many patients with psoriasis access to guidelines-based MTX therapy for the first time. Click here to view full Press release

Press release – Alacare®

Innovative therapeutic for the treatment of mild actinic keratoses – first self-adhesive patch for PDT The skin lesion actinic keratosis is associated with an estimated prevalence of up to 60 % in certain populations and bears a high disease burden being considered as precancerous The treatment option with the ALA-PDT patch has not only been […]

Medac er ikke ansvarlig for indeholdet på andre websider!